Table 4

Number of events (relapses) in the node negative (known follow up n = 130) and node positive (n = 159) subgroups

	Node negative patients (T1-4 N0 M0)				Node positive patients (T1-4 N1-2 M0)
	Total	Events	%	p Value	Total	Events	%	p Value
Median observation time for disease free survival, 82 months. Statistical calculation using log rank test.
Univariate statistical calculation using χ² test.
Receptor status: positive, ER positive and/or PR positive; negative, ER negative and PR negative; detection by immunohistochemistry.
ER, oestrogen receptor; NS, not significant; PCNA, proliferating cell nuclear antigen; PR, progesterone receptor.
Age (years)
< 50	47	9	19.2		55	25	45.5
> 50	83	23	27.7	NS	104	61	58.7	NS
Menopausal status
Pre	35	6	17.1		46	22	47.8
Peri	21	4	19.1		20	10	50.0
Post	74	22	29.7	NS	93	54	58.1	NS
Tumour size (cm)
< 2	63	14	13.0		47	19	40.4
2–5	59	16	27.1		80	43	53.8
> 5	8	2	25.0	NS	32	24	75.0	< 0.00001
Tumour grade
GI	23	3	13.0		23	9	39.1
GII	72	20	27.8		80	35	43.8
GIII	35	9	25.7	NS	56	42	75.0	< 0.00001
Receptor status
Negative	38	12	31.6		52	38	73.1
Positive	90	19	21.1	NS	104	47	45.2	0.00001
PCNA
< 10%	62	13	21.0		65	27	41.5
10–49%	43	10	23.4		47	28	59.6
> 50%	22	8	36.4	NS	44	29	65.9	0.037
Her2/neu
Negative	102	24	23.5		116	56	48.3
Positive	25	7	28	NS	38	29	76.3	0.0017
p53
Negative	82	18	22.0		87	40	46.0
Positive	46	13	28.3	NS	67	44	65.7	0.005
p21^waf
Negative	87	23	26.4		107	63	58.9
Positive	43	9	20.9	NS	52	23	44.2	NS
Total	130	32	24.6		159	86	54.1

p21^waf correlates with DNA replication but not with prognosis in invasive breast cancer

Latest from JCP Education